Serotonin 

 448 Products   448 Products   1070 Diseases   113911 News 


«12...2728293031323334353637...11171118»
  • ||||||||||  clozapine / Generic mfg.
    Journal:  Insight and the Capacity to Refuse Treatment with Electroconvulsive Therapy. (Pubmed Central) -  Jul 4, 2024   
    As well as deciding whether ECT was appropriate in the circumstances, the Court considered whether there were alternative treatments including another trial of the oral antipsychotic clozapine. This article reviews issues relating to lack of insight in persons with psychotic illness and relevant considerations for determining capacity to decline ECT.
  • ||||||||||  fluoxetine / Generic mfg.
    Preclinical, Journal:  Effect of depression and the antidepressant fluoxetine on osseointegration-A pre-clinical in (Pubmed Central) -  Jul 4, 2024   
    Depression and fluoxetine negatively affect bone density and implant osseointegration independently, and this damaging effect is exacerbated when both factors are present. The mechanism may be related to the dysregulation of the hypothalamic-pituitary-adrenal axis and inflammation in the body.
  • ||||||||||  Fintepla (low-dose fenfluramine) / UCB
    Review, Journal:  Practical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox-Gastaut syndrome in clinical practice. (Pubmed Central) -  Jul 4, 2024   
    PLAIN LANGUAGE SUMMARY: Fenfluramine is used to treat seizures in individuals with Dravet syndrome and Lennox-Gastaut syndrome, but there are a range of issues that clinicians may face when treating patients. This review highlights four patients from the authors' everyday clinical work and offers guidance and practical considerations by neurologists with expertise in managing these complex conditions related to drug interactions, dosing, and side effects associated with fenfluramine.
  • ||||||||||  escitalopram / Generic mfg.
    Journal, Adverse events:  Yawning as a Rare Side Effect With Increased Escitalopram Dose: A Case Report. (Pubmed Central) -  Jul 4, 2024   
    Clinically, differentiating yawning induced by escitalopram treatment from that in depression can be a diagnostic hurdle. Awareness and recognition of this lesser known side effect can improve patient outcomes by allowing for timely adjustments and easing the discomfort.
  • ||||||||||  Aduhelm (aducanumab) / Neurimmune, Eisai, Leqembi (lecanemab-irmb) / Biogen, BioArctic, Eisai, Kisunla (donanemab-azbt) / Eli Lilly
    Review, Journal:  New and emerging drug therapies for Alzheimer disease. (Pubmed Central) -  Jul 4, 2024   
    Established drug therapies for Alzheimer disease (cholinesterase inhibitors and memantine) do not modify the disease course and provide only modest clinical benefit...At the time of writing, two monoclonal antibodies targeting the amyloid-beta protein (aducanumab and lecanemab) have been approved in the USA, and two agents (lecanemab and donanemab) are under evaluation by the Therapeutic Goods Administration in Australia...The burden of dementia is greatest in the older population where mixed dementia pathology dominates; the relationship between biomarkers, clinical phenotype and pathology attenuates; and frailty and comorbidity impact cognition. This creates challenges in identifying effective therapies for the group where dementia is most prevalent.
  • ||||||||||  Review, Journal:  Pharmacological treatment of posttraumatic stress disorder (Pubmed Central) -  Jul 3, 2024   
    Venlafaxine, in particular, has shown good effectiveness in studies, whereas risperidone has shown lower effectiveness in augmentation...Treatment of trauma-related nightmares can be attempted with doxazosin or clonidine. In contrast, there are limited empirical data available for sleep disorders associated with PTSD, but the pharmacological treatment of insomnia can provide some guidance.
  • ||||||||||  Biomarker, Journal:  Pharmacogenetic Testing or Therapeutic Drug Monitoring: A Quantitative Framework. (Pubmed Central) -  Jul 3, 2024   
    However, genotype prevalence and the relative influence of genotypes on the PK, as well as the ability of TDM to accurately estimate AUC with a limited number of samples, had an impact. The results could be used to support clinical decision making when considering other factors, such as the probability for severe side effects.
  • ||||||||||  clozapine / Generic mfg.
    Journal:  Clozapine Proficiency as a Milestone in Psychiatric Training. (Pubmed Central) -  Jul 3, 2024   
    The results could be used to support clinical decision making when considering other factors, such as the probability for severe side effects. No abstract available
  • ||||||||||  chlorpromazine / Generic mfg.
    Retrospective data, Review, Journal:  Baseline Antipsychotic Dose and Transition to Psychosis in Individuals at Clinical High Risk: A Systematic Review and Meta-Analysis. (Pubmed Central) -  Jul 3, 2024   
    To test whether the negative prognostic effect of baseline antipsychotic exposure in individuals at CHR-P follows a dose-effect pattern, as indicated by mean chlorpromazine equivalent doses (CPZ-ED)...In individuals at CHR-P who were exposed to antipsychotics at baseline, those receiving higher antipsychotic doses demonstrated an increased likelihood of transitioning to psychosis. This meta-analytic evidence of putative dose-effect association confirms that baseline antipsychotic exposure and the corresponding dosage carry salient prognostic information that could improve current CHR-P criteria-based risk stratification at inception.
  • ||||||||||  Firdapse (amifampridine) / BioMarin, Catalyst Pharma, Dydo Pharma, Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
    Trial completion date, Trial primary completion date:  Effect of Amifampridine on Neuromuscular Transmission in Patients Treated With OnabotulinumtoxinA (clinicaltrials.gov) -  Jul 3, 2024   
    P1,  N=20, Recruiting, 
    Research on antipsychotics needs to be person-centred and prioritise factors that are of interest to people with lived experience of schizophrenia. Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Sep 2024
  • ||||||||||  Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
    Trial completion date, Trial primary completion date:  Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms (clinicaltrials.gov) -  Jul 3, 2024   
    P2/3,  N=80, Recruiting, 
    Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Sep 2024 Trial completion date: Aug 2024 --> Aug 2026 | Trial primary completion date: Jun 2024 --> Jun 2025
  • ||||||||||  clozapine / Generic mfg.
    Journal:  Chemogenetic Tools and their Use in Studies of Neuropsychiatric Disorders. (Pubmed Central) -  Jul 3, 2024   
    It has been mainly the G-protein coupled receptors (GPCRs) selectively responding to clozapine-N-oxide (CNO), namely Designer Receptors Exclusively Activated by Designer Drugs (DREADDs), that have been employed in research...Therefore, chemogenetics presents a powerful tool for investigating the underlying mechanisms causing the disease and revealing the link between the circuit dysfunction and the behavioral or cognitive symptoms observed in patients. It could also contribute to the development of more effective treatments.
  • ||||||||||  sertraline / Generic mfg.
    Journal:  A novel approach to treating post-stroke depression: administration of Botulinum Toxin A via local facial injection. (Pubmed Central) -  Jul 3, 2024   
    Ultimately, number of participants in the BoNT-A group (n?=?32) and Sertraline group (n?=?33)...The analysis revealed significant differences in measurements of the Hamilton Depression Scale (HAMD) (F(770)?=?12.547, p?=?0.000), Hamilton Anxiety Scale (HAMA) (F(951)?=?10.422, p?=?0.000), Self-Rating Depression Scale (SDS) (F(1385)?=?10.607, p?=?0.000), and Self-Rating Anxiety Scale (SAS) (F(1482)?=?11.491, p?=?0.000). BoNT-A treatment effectively reduces depression symptoms in patients with PSD on a continuous basis.
  • ||||||||||  dihydroergotamine mesylate injection / Generic mfg.
    Journal, Real-world evidence, Real-world:  Real-world approaches to outpatient treatment of status migrainosus: A survey study. (Pubmed Central) -  Jul 3, 2024   
    Outpatient management with one or more medications for home use was preferred by most respondents; few opted for ED referrals. Finally, corticosteroids, NSAIDs, neuroleptics, triptans, and DHE were the top five preferred treatments for home SM management.
  • ||||||||||  pregabalin / Generic mfg., duloxetine / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  Hyperbaric Oxygen Therapy Compared to Pharmaceutical in Fibromyalgia With Emotional Trauma (clinicaltrials.gov) -  Jul 3, 2024   
    P=N/A,  N=48, Completed, 
    Finally, corticosteroids, NSAIDs, neuroleptics, triptans, and DHE were the top five preferred treatments for home SM management. Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Nov 2023 | Trial primary completion date: Dec 2024 --> Nov 2023
  • ||||||||||  tianeptine / Generic mfg.
    Trial completion date, Trial primary completion date:  Tianeptine for Treatment Resistant Depression (clinicaltrials.gov) -  Jul 3, 2024   
    P4,  N=75, Recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Nov 2023 | Trial primary completion date: Dec 2024 --> Nov 2023 Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Jun 2025 --> Dec 2025
  • ||||||||||  Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
    Review, Journal:  Botulinum toxin (Pubmed Central) -  Jul 2, 2024   
    Gender-specific causes of urgency and urge incontinence in women are differentiated from the diagnosis of OAB and require priority treatment. On the basis of diagnostic examination results, an algorithm for invasive second-line treatment of OAB is presented, since overly liberal utilization of onabotulinumtoxinA in therapy-naive OAB patients has not proven superiority over oral antimuscarinergic standard therapy, which can only be explained by improper patient selection.
  • ||||||||||  Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
    Review, Journal:  Botulinum toxin in male lower urinary tract symptoms (LUTS): What can we expect? (Pubmed Central) -  Jul 2, 2024   
    On the basis of diagnostic examination results, an algorithm for invasive second-line treatment of OAB is presented, since overly liberal utilization of onabotulinumtoxinA in therapy-naive OAB patients has not proven superiority over oral antimuscarinergic standard therapy, which can only be explained by improper patient selection. But first of all, a
  • ||||||||||  trazodone ER / Generic mfg.
    Journal, HEOR:  Economic burden of comorbid insomnia in 5 common medical disease subgroups. (Pubmed Central) -  Jul 2, 2024   
    But first of all, a In this national analysis, both untreated comorbid insomnia and comorbid insomnia treated with commonly prescribed insomnia medications were associated with increased health care resource utilization and costs across most points of service.
  • ||||||||||  Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
    Journal:  "Prompt" for PREEMPT: Dotting the I's and Crossing the T's With Ultrasound. (Pubmed Central) -  Jul 2, 2024   
    The management of chronic migraine (CM) underwent a significant shift with the introduction of onabotulinumtoxin A (BoNT-A) injections following the landmark PREEMPT trial in 2010...This article highlights the potential of US-guided injections to enhance accuracy, safety, and efficacy in CM treatment. By providing real-time visualization and addressing anatomical variations, US guidance offers a promising avenue for optimizing BoNT-A delivery, minimizing adverse effects, and ensuring therapeutic success.
  • ||||||||||  modafinil / Generic mfg.
    Compulsive Gambling Associated With Modafinil: A Case Report (A6) -  Jul 2, 2024 - Abstract #EAN2024EAN_3249;    
    She was diagnosed with NT1 and commenced modafinil therapy started at a dose of 100?mg daily together with clomipramine 25?mg daily. We described new-onset impairment of impulse control after taking modafinil which has been more commonly described in patients receiving dopamine agonist therapy.
  • ||||||||||  venlafaxine / Generic mfg.
    Persistent Postural Perceptual Dizziness (PPPD) In The Neurology Clinic (A3) -  Jul 2, 2024 - Abstract #EAN2024EAN_3092;    
    PPPD is a relatively common neurological condition, should be considered in patients with chronic vestibular symptoms which result in significant functional morbidity. In this cohort, treatment with Venlafaxine and vestibular physiotherapy resulted in significant improvement in symptoms.